NEW YORK, Jan. 2, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Todaywe are offering reports on AUPH, ALDR, AKAO, and IMMU which can be accessed for free by signing up to www.wallstequities.com/registration. On Friday, December 29, 2017, US markets saw broad based losses with seven out
On Friday, shares in Victoria, Canada headquartered Aurinia Pharmaceuticals Inc. recorded a trading volume of 1.37 million shares, which was above their three months average volume of 1.23 million shares. The stock ended the session 2.58% lower at $4.53. The Company's shares have gained 110.70% in the past twelve months and 115.71% on an YTD basis. The stock is trading below its 50-day moving averages by 14.91%. Moreover, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have a Relative Strength Index (RSI) of 36.37. Get the full research report on AUPH for free by clicking below at:
Bothell, Washington headquartered Alder Biopharmaceuticals Inc.'s stock closed the day flat at $11.45 with a total trading volume of 608,468 shares. The Company's shares have advanced 9.57% in the past month. The stock is trading above its 50-day moving average by 5.56%. Additionally, shares of Alder Biopharma, which discovers, develops, and commercializes therapeutic antibodies in the US, Australia, and Ireland, have an RSI of 56.10. Free research on ALDR can be accessed at:
Shares in South San Francisco, California-based Achaogen Inc. recorded a trading volume of 1.19 million shares, which was above their three months average volume of 903.41 thousand shares. The stock ended last Friday's trading session 2.54% lower at $10.74. The stock is trading below its 50-day moving average by 11.49%. Furthermore, shares of Achaogen, which discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the US, have an RSI of 43.04. Sign up today for the free research report on AKAO at:
Morris Plains, New Jersey headquartered Immunomedics Inc.'s stock finished Friday's session 0.98% lower at $16.16 with a total trading volume of 4.16 million shares, which was above their three months average volume of 3.25 million shares. The Company's shares have advanced 53.32% in the last month, 15.59% over the previous three months, 342.74% in the past twelve months, and 340.33% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 39.11% and 72.21%, respectively. Additionally, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have an RSI of 74.23. Wall St. Equities' research coverage also includes the downloadable free report on IMMU at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit: https://wallstequities.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----aurinia-pharma-alder-biopharma-achaogen-and-immunomedics-300576338.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Pets can give you diseases. Surprised? You may love your pet but beware! Your pets might be ...
Water is essential to balance body fluids, boost brain function, improve digestion, prevent ...
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...View All